🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

15 recruiting trials

for Intermediate Risk Acute Myeloid Leukemia

Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia NCT04659616Phase 12 sites📍 Portland📍 Dallas OHSU Knight Cancer Institute · Tests: Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Cytarabine, Daunorubicin Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML. NCT06483906Phase 21 site📍 Shanghai Shanghai General Hospital, Shanghai Jiao Tong University Sc… · Tests: Venetoclax, Azacitidine and Homoharringtonine Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR NCT02416388Phase 2, Phase 356 sites📍 Amiens📍 Angers📍 Argenteuil University Hospital, Angers · Tests: Idarubicin, Daunorubicin, HD Cytarabine, Cyclosporine, Methotrexate VA Consolidation in Intermediate-Risk AML NCT07672262Phase 21 site📍 Suzhou The First Affiliated Hospital of Soochow University · Tests: Venetoclax and Azacitidine, Cytarabine ± Anthracycline Intermediate-dose HAD Regimen for CEBPA Double-mutated AML NCT06529250NA1 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: HAD, Daunorubicin+Cytarabine Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial) NCT05554393Phase 2187 sites📍 Birmingham📍 Tucson📍 Tucson National Cancer Institute (NCI) · Tests: Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Cytarabine, Daunorubicin Hydrochloride Effectiveness of Medium-Dose Cytarabine Combined With Venetoclax for Consolidation Therapy in Elderly Patients With Intermediate to High-Risk Acute Myeloid Leukemia NCT06990321Phase 31 site📍 Changchun Yehui Tan · Tests: Intermediate-dose Cytarabine in Combination with Venetoclax A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients NCT06928376Phase 21 site📍 Beijing Chinese PLA General Hospital · Tests: Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor, "3+7" Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction NCT04049539Phase 1, Phase 22 sites📍 Sacramento📍 Columbus Ohio State University Comprehensive Cancer Center · Tests: Liposome-encapsulated Daunorubicin-Cytarabine Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AML NCT07304232Phase 25 sites📍 Shijiazhuang📍 Harbin📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: Chidamide Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients NCT06394011Phase 21 site📍 Suzhou The First Affiliated Hospital of Soochow University · Tests: venetoclax, azacitidine and HAAG regimen Gilteritinib Plus VA Followed By Consolidation Chemotherapy in Newly Diagnosed FLT3-ITD+ AML NCT07259707Phase 21 site📍 Hangzhou First Affiliated Hospital of Zhejiang University · Tests: GVA + HDAC Consolidation & Gilteritinib Maintenance Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML NCT04168502Phase 348 sites📍 Alessandria📍 Ancona📍 Ascoli Piceno Gruppo Italiano Malattie EMatologiche dell'Adulto · Tests: Gemtuzumab Ozogamicin CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics NCT05260528Phase 235 sites📍 Amiens📍 Angers📍 Avignon Centre Hospitalier Universitaire de Nice · Tests: Cytarabine and Idarubicin, CPX-315 Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1 NCT06744504Phase 31 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: cytarabine, daunorubicin, idarubicin, cyclophosphamide
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy